Sobi gains FDA approval for Gamifant to treat HLH/MAS
The FDA has approved Sobi's Gamifant (emapalumab) to treat adults and children with HLH/MAS associated with Still’s disease, including sJIA.
The FDA has approved Sobi's Gamifant (emapalumab) to treat adults and children with HLH/MAS associated with Still’s disease, including sJIA.
What's Your Reaction?
